NeuroFGL 

 ________________

The primary aim of the NeuroFGL program is to reach clinical proof-of-concept for the promising and novel regenerative therapy, FGLs, in a three year clinical proof of concept program in Alzheimer's disease. To secure achievement of this aim within the time and resources available, surrogate markers demonstrating FGLs' effect on neurogenesis will be applied. This will increase the chances of detecting a functional effect of FGLs with the objective of demonstrating clinical proof-of-concept during the project.

The surrogate marker work to be carried out by NeuroFGL will include developing a new PET tracer ([18F]-FLT) and assessment of functional brain connectivity by electroencephalography (‘EEG'). [18F]-FLT is a bromodeoxyuridin analogue for detecting neurogenesis in vivo applicable for the development of FGLs but it will also potentially support the development of future neuro-regenerative therapies. The program includes assessment of functional brain connectivity by EEG to measure neural oscillations. These oscillations are a fundamental mechanism for enabling coordinated activity during normal brain functioning and are therefore a crucial target for the development of neuro-regenerative therapies.